UC Students Observe The Legacy of Martin Luther King Jr.

Three UC student organizations – Alpha Phi Alpha Fraternity, the United Black Student Association and the African American Cultural and Research Center (AACRC) – are co-sponsoring a tribute to Martin Luther King Jr. on Wednesday, Jan. 14.

Beginning at 6:06 p.m. on Jan. 14, students will assemble on McMicken Commons for a “March of Remembrance.” The march is organized by the University of Cincinnati chapter of Alphi Phi Alpha Fraternity. King was a member of Alpha Phi Alpha Fraternity, the nation’s first intercollegiate fraternity for African American college students.

The march will proceed to the UC Event Pavilion where the program, “A Tribute to Martin Luther King Jr. – Watch Out for Dream Snatchers,” will begin at 7 p.m. The program will begin with a performance by UC’s African American Cultural and Research Center (AACRC) Choir. 

The guest speaker is Nell J. Lewis, a retired educator and former director of the Ledonia Wright Cultural Center for East Carolina University. She dedicated her career to building diversity in education. Born in Jamesville, N.C., her biography states that she was among the first African American students to integrate Jamesville High School in 1965.

The program is free and open to the public. For more information, contact Stacy Downing, assistant director for the AACRC, at 513-556-1177 or check the AACRC web site.

Related Stories


Ongoing quest for justice a life-changer for all parties

December 7, 2023

The Ohio Innocence Project and its student fellows, past and present, recently marked 20 years working to exonerate the wrongfully convicted. OIP co-founder and director Mark Godsey, as well as past OIP fellows and Cincinnati Law alumni, Eric Eckes, Law ’08, and Simar Khera, Law ’15, spoke about their shared experience and its life-changing impact.


UC Gardner Neuroscience Institute to lead new national stroke...

December 7, 2023

The UC Gardner Neuroscience Institute has received $19 million in federal funding from the National Institutes of Health to serve as the lead center for a Phase 2 clinical trial that will study the efficacy of a new monoclonal antibody treatment for patients ineligible for currently available treatments.

Debug Query for this